A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Conditions
- Colorectal Neoplasms
- Interventions
- Registration Number
- NCT06750094
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 700
- Have histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Participants must have recurrent, unresectable or metastatic disease
- Be diagnosed to have KRAS, NRAS, and BRAF wild-type (WT) tumor as determined by local testing
- Must agree to the submission of fresh or archival tumor tissue post-progression from the most recent therapy, if clinically feasible
- Have measurable disease according to RECIST v1.1
- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1
- Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy
- Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
- Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI
- Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
- Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor
- Has prior exposure to irinotecan, any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Amivantamab + FOLFIRI Amivantamab Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab + FOLFIRI 5-fluorouracil Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab + FOLFIRI Irinotecan Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab or Bevacizumab + FOLFIRI Cetuximab Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab or Bevacizumab + FOLFIRI Bevacizumab Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab or Bevacizumab + FOLFIRI 5-fluorouracil Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab or Bevacizumab + FOLFIRI Leucovorin calcium/Levoleucovorin Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm B: Cetuximab or Bevacizumab + FOLFIRI Irinotecan Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. Arm A: Amivantamab + FOLFIRI Leucovorin calcium/Levoleucovorin Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Up to 2 years 1 month PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v)1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date.
Overall Survival (OS) Up to 4 years 4 months OS is defined as the time from the date of randomization to the date of participant's death due to any cause.
- Secondary Outcome Measures
Name Time Method Progression Free Survival After Subsequent Therapy (PFS2) Up to 4 years 4 months PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent systemic anticancer therapy, based on investigator assessment or death, whichever comes first.
Objective Response Rate as Assessed by Investigator Up to 4 years 4 months ORR is defined as the percentage of randomized participants achieving PR or CR, as assessed by investigator.
Objective Response Rate (ORR) as Assessed by BICR Up to 4 years 4 months ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by BICR using RECIST v1.1 criteria.
Progression Free Survival as Assessed by Investigator Up to 4 years 4 months PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by investigator.
Duration of Response (DoR) as Assessed by BICR Up to 4 years 4 months DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by BICR.
Duration of Response as Assessed by Investigator Up to 4 years 4 months DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by investigator.
Disease Control Rate (DCR) as Assessed by BICR Up to 4 years 4 months DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as defined by BICR using RECIST v1.1.
Disease Control Rate as Assessed by Investigator Up to 4 years 4 months DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as assessed by investigator.
Time to Treatment Failure Up to 4 years 4 months Time to treatment failure is defined as time from randomization to discontinuation of therapy for any reason including death, progression, toxicity, or initiation of new anticancer therapy.
Curative Resection (R0) Rate Up to 4 years 4 months Curative resection (R0) rate is defined as the percentage of randomized participants who underwent curative surgery.
Number of Participants with Adverse Events (AEs) by Severity Up to 4 years 4 months An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.
Number of Participants with Abnormalities in Laboratory Values Up to 4 years 4 months Participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score From baseline up to 4 years 4 months The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C30 Up to 4 years 4 months Time to worsening in symptoms and functioning as measured by EORTC QLQ-C30 score will be reported. The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C29) Score From baseline up to 4 years 4 months The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms.
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C29 Score Up to 4 years 4 months Time to worsening in symptoms and functioning as measured by EORTC QLQ-CR29 will be reported. EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms. Change from baseline in the EORTC QLQ-CR29 score will be reported.
Overall Side Effect Burden as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Item 168 Scale Score Up to 4 years 4 months EORTC item 168 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much. Higher scores indicates severe symptoms.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (168)
Assuta MC
🇮🇱Tel Aviv, Israel
Jolimont
🇧🇪Haine Saint Paul La Louviere, Belgium
Az Groeninge
🇧🇪Kortrijk, Belgium
Universitair Ziekenhuis Leuven
🇧🇪Leuven, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Fundacao Universidade de Caxias do Sul
🇧🇷Caxias do Sul, Brazil
Fundacao Doutor Amaral Carvalho
🇧🇷Jau, Brazil
Hospital Santa Izabel Santa Casa de Misericordia da Bahia
🇧🇷Salvador, Brazil
Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base
🇧🇷Sao Jose do Rio Preto, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
🇧🇷Vitoria, Brazil
Peking University First Hospital
🇨🇳Beijing, China
Centrul Medical Unirea SRL
🇷🇴Brasov, Romania
Hosp. Clinico Univ. de Valencia
🇪🇸Valencia, Spain
Istituto Dei Tumori Di Milano
🇮🇹Milano, Italy
Ironwood Cancer and Research Center
🇺🇸Chandler, Arizona, United States
St. Bernard's Medical Center
🇺🇸Jonesboro, Arkansas, United States
CBCC Global Research
🇺🇸Bakersfield, California, United States
Cancer and Blood Specialty Clinic
🇺🇸Los Alamitos, California, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Providence Medical Foundation
🇺🇸Santa Rosa, California, United States
Torrance Memorial Physicians Network
🇺🇸Torrance, California, United States
University of Colorado Denver Anschultz Medical Campus
🇺🇸Aurora, Colorado, United States
Eastern Connecticut Hematology & Oncology Assoc.
🇺🇸Norwich, Connecticut, United States
Mount Sinai Medical Center Campus
🇺🇸Miami Beach, Florida, United States
AdventHealth Cancer Institute
🇺🇸Orlando, Florida, United States
Grady Memorial Hospital
🇺🇸Atlanta, Georgia, United States
Winship Cancer Institute Emory University
🇺🇸Atlanta, Georgia, United States
Mary Bird Perkins Cancer Center
🇺🇸Baton Rouge, Louisiana, United States
MedStar Franklin Square Medical Center
🇺🇸Baltimore, Maryland, United States
Cancer And Hematology Centers of Western Michigan PC
🇺🇸Grand Rapids, Michigan, United States
Hattiesburg Clinic
🇺🇸Hattiesburg, Mississippi, United States
Washington University School Of Medicine
🇺🇸Saint Louis, Missouri, United States
Nebraska Cancer Specialists
🇺🇸Omaha, Nebraska, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
New York Cancer and Blood Specialists
🇺🇸Shirley, New York, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Scott And White Memorial Hospital
🇺🇸Temple, Texas, United States
Providence Regional Cancer System
🇺🇸Lacey, Washington, United States
Concord Hospital
🇦🇺Concord, Australia
Warringal Private Hospital
🇦🇺Heidelberg, Australia
Queen Elizabeth Hospital
🇦🇺South Woodville, Australia
Western Health Sunshine Hospital
🇦🇺St Albans, Australia
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
Beijing Friendship Hospital Capital Medical University
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
West China Hospital of Sichuan University
🇨🇳Chengdu, China
Ganzhou Cancer Hospital
🇨🇳Ganzhou, China
Sun Yat Sen University Cancer Center
🇨🇳Guangzhou, China
The Sixth Affiliated Hospital Sun Yat sen University
🇨🇳Guangzhou, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
The Second Affiliated Hospital of Zhejiang University
🇨🇳Hangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Huizhou Central People's Hospital
🇨🇳Huizhou, China
Gansu Provincial Cancer Hospital
🇨🇳Lanzhou, China
The First Affiliated Hospital of NanChang University
🇨🇳Nanchang, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
Institut Sainte Catherine
🇫🇷Avignon Cedex 9, France
Hopital Haut Leveque
🇫🇷Pessac, France
CHU De Poitiers
🇫🇷Poitiers Cedex, France
Charite Universitatsmedizin Berlin Campus Virchow Klinikum
🇩🇪Berlin, Germany
Krankenhaus NorthWest
🇩🇪Frankfurt am Main, Germany
Klinikum der Universitaet Muenchen
🇩🇪Munich, Germany
Prince Of Wales Hospital
ðŸ‡ðŸ‡°Shatin, Hong Kong
Markhot Ferenc Oktatokorhaz es Rendelointezet
ðŸ‡ðŸ‡ºEger, Hungary
Pecsi Tudomanyegyetem
ðŸ‡ðŸ‡ºPecs, Hungary
Rajiv Gandhi Cancer Institute and Research Centre
🇮🇳Delhi, India
Asian Institute Of Gastroenterology
🇮🇳Hyderabad, India
B P Poddar Hospital and Medical research Limited
🇮🇳Kolkata, India
Tata Memorial Hospital
🇮🇳Mumbai, India
Deenanath Mangeshkar Hospital and Research Centre
🇮🇳Pune, India
Christian medical
🇮🇳Vellore, India
Yitzhak Shamir Medical Center
🇮🇱Beer Yaakov, Israel
Rambam Medical Center
🇮🇱Haifa, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Rabin Medical Center
🇮🇱Petach Tikva, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv Yafo, Israel
Istituto Oncologico Veneto - IRCCS
🇮🇹Padova, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Azienda Sanitaria Universitaria Friuli Centrale ASU FC
🇮🇹Udine, Italy
Chiba Cancer Center
🇯🇵Chiba, Japan
National Cancer Center Hospital
🇯🇵Chuo Ku, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Aichi Cancer Center
🇯🇵Nagoya Shi, Japan
Osaka International Cancer Institute
🇯🇵Osaka City, Japan
Kindai University Hospital
🇯🇵Osaka Sayama shi, Japan
National Hospital Organization Osaka National Hospital
🇯🇵Osaka-Shi, Japan
Osaka University Hospital
🇯🇵Suita-shi, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Pulau Pinang
🇲🇾Georgetown, Malaysia
Hospital Raja Permaisuri Bainun
🇲🇾Ipoh, Malaysia
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Hospital Umum Sarawak
🇲🇾Kuching, Malaysia
Institut Kanser Negara Clinical Research Center
🇲🇾Putrajaya, Malaysia
Centro Oncologico de Chihuahua
🇲🇽Chihuahua, Mexico
Centro Oncologico Personalizado Cope S De R L De C V
🇲🇽Ciudad de Mexico, Mexico
Actualidad Basada En La Investigacion Del Cancer
🇲🇽Guadalajara, Mexico
Oncocenter
🇲🇽Puebla, Mexico
Cuidados Oncologicos
🇲🇽Queretaro, Mexico
Health Pharma Queretaro SA de CV
🇲🇽Queretaro, Mexico
Meander Medisch Centrum
🇳🇱Amersfoort, Netherlands
Radboud University Medical Center
🇳🇱Nijmegen, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands
ETZ TweeSteden
🇳🇱Tilburg, Netherlands
Wojewodzki Szpital Specjalistyczny
🇵🇱Biala Podlaska, Poland
Bialostockie Centrum Onkologii im Marii Sklodowskiej Curie w Bialymstoku
🇵🇱Bialystok, Poland
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
🇵🇱Brzozow, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach
🇵🇱Gliwice, Poland
Instytut Centrum Zdrowia Matki Polki
🇵🇱Lodz, Poland
SPZOZ Ministerstwa Spraw Wewnetrznych z Warminsko Mazurskim Centrum Onkologii w Olsztynie
🇵🇱Olsztyn, Poland
SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego
🇵🇱Opole, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Pan American Center for Oncology Trials LLC
🇵🇷San Juan, Puerto Rico
Ponderas Academic Hospital
🇷🇴Bucuresti, Romania
Clinica de Oncologie Sf Nectarie
🇷🇴Craiova, Romania
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. Ramon Y Cajal
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Sahlgrenska Universitetssjukhuset
🇸🇪Gothenburg, Sweden
Skanes universitetssjukhus
🇸🇪Lund, Sweden
Sodersjukhuset
🇸🇪Stockholm, Sweden
Karolinska Universitetssjukhuset
🇸🇪Stockholm, Sweden
Uppsala University
🇸🇪Uppsala, Sweden
Chang Gung Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Ramathibodi Hospital
🇹ðŸ‡Bangkok, Thailand
Siriraj Hospital
🇹ðŸ‡Bangkok, Thailand
Chiang Mai University
🇹ðŸ‡Chiang Mai, Thailand
Songklanagarind hospital
🇹ðŸ‡Songkhla, Thailand
Gulhane Egitim ve Arastirma Hastanesi
🇹🇷Ankara, Turkey
Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
🇹🇷Ankara, Turkey
Gazi University Hospital
🇹🇷Ankara, Turkey
Bakirkoy Training and Research Hospital
🇹🇷Istanbul, Turkey
Marmara University Pendik Training Hospital
🇹🇷İstanbul, Turkey
Necmettin Erbakan University Meram Medical Faculty
🇹🇷Konya, Turkey
Sakarya University Training and Research Hospital
🇹🇷Sakarya, Turkey
Castle Hill Hospital
🇬🇧Hull, United Kingdom
St James University Hospital
🇬🇧Leeds, United Kingdom
St Bartholomew's Hospital
🇬🇧London, United Kingdom
University College Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital
🇬🇧London, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, United Kingdom